Eli Lilly’s Weight-Loss Boom Hits an Uneven Road

Eli Lilly has been riding high on the success of its GLP-1 weight-loss medications. However, recent numbers suggest that the trend may be plateauing. According to a report, employer coverage of these medicines has dropped from 72% in 2025 to 60% in 2026.

This decline represents a fundamental shift in the way employers approach prescription costs. For years, companies have been willing to foot the bill for expensive medications like Zepbound and Mounjaro, hoping that long-term health benefits would justify the expense. However, as prices continue to rise and savings take longer than expected to materialize, some employers are rethinking their strategy.

The 60% coverage rate is still significant, but it’s a drop of 12 percentage points in just one year. This decline is concerning given the rising costs of healthcare overall. Employers already spend nearly a quarter of their healthcare budgets on pharmacy benefits, and GLP-1 medications are among the most expensive prescriptions.

As employers pull back from covering these treatments, more people will be forced to pay out-of-pocket for their medication. This can create a barrier to access, particularly for those who cannot afford the steep prices. Half of all new Zepbound prescriptions are now filled as self-pay, which is a worrisome trend.

One argument against employer coverage for GLP-1s is that these savings take time to materialize. Employers budget on annual cycles, while health benefits unfold over many years. However, this perspective overlooks the financial burden that these medications place on companies.

The weight-loss boom is shifting shape, but whether this represents a stall or an evolution remains to be seen. Eli Lilly’s success story has hit a roadblock. As the pharmaceutical industry grapples with rising costs and changing employer attitudes, one question looms large: what does this mean for the future of weight-loss treatments?

The Economic Reality of GLP-1s

GLP-1 medicines are expensive because they mimic a gut hormone that regulates appetite and blood sugar. These medications have revolutionized type 2 diabetes and obesity treatment, but their high price tags make them unaffordable for many patients.

Employers finance most prescription coverage through their health plans, creating a perverse incentive. When employers drop a category, patient out-of-pocket costs rise sharply, and prescriptions shift toward cash-pay channels. This is happening with GLP-1s; as employer coverage declines, more people are forced to pay out-of-pocket for these treatments.

The Human Cost of Unaffordable Medications

The human cost of unaffordable medications cannot be overstated. When patients are unable to access the treatment they need, they face financial burdens and put their health at risk. Obesity and diabetes are complex conditions that require ongoing management, but these treatments can be life-changing for many people.

As employer coverage declines, it’s essential to acknowledge the real-world consequences of this trend. We must recognize that unaffordable medications create a barrier to access, particularly for vulnerable populations. This is not just an economic issue; it’s also a matter of public health.

What’s Next for Eli Lilly?

Eli Lilly can still navigate this challenge by partnering with employers and insurers to develop more affordable pricing models or investing in research and development to create new treatments that are more accessible to patients. The future of GLP-1s depends on the complex interplay of economic, social, and medical factors. As this trend continues to unfold, the pharmaceutical industry will need to adapt to changing employer attitudes and rising costs.